Tiletamine Hcl & Zolazepam Hcl)

Verify with FDA CVM →

15 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
5
Deaths Reported
3330.0%
Death Rate

Active Ingredients

Tiletamine Hcl & Zolazepam Hcl)

Administration Routes

UnknownIntramuscularIntravenousSubcutaneous

Species Affected

Dog 9
Cat 6

Most Affected Breeds

Dog (unknown) 3
Cat (other) 3
Retriever - Golden 2
Domestic Shorthair 2
Retriever - Labrador 1
Mixed (Dog) 1
Spaniel (unspecified) 1
Bulldog 1
Domestic Longhair 1

Most Reported Reactions

Circling - neurological disorder (see also 'Behavioural disorders') 2
Hernia NOS 2
Surgical site disorder 2
Fever 2
Sudden death 2
Sedation 1
Bradycardia 1
Apnoea 1
Depressed ocular reflex 1
Laboured breathing 1
Loose stool 1
Limb weakness 1

Outcome Breakdown

Recovered/Normal
6 (40.0%)
Ongoing
4 (26.7%)
Died
3 (20.0%)
Euthanized
2 (13.3%)

Data Summary

Metric Value
Total adverse event reports 15
Reports involving death 5
Case-fatality rate (reported events) 3330.0%
Distinct species in reports 2
Distinct breeds in reports 9
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Tiletamine Hcl & Zolazepam Hcl) Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 15 adverse event reports referencing Tiletamine Hcl & Zolazepam Hcl), including 5 reports in which the animal died — a 3330.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Tiletamine Hcl & Zolazepam Hcl). Reported administration routes include Unknown, Intramuscular, Intravenous, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Tiletamine Hcl & Zolazepam Hcl) reports are Dog (9 reports), Cat (6 reports), with Dog accounting for the largest share. Within those species, Dog (unknown) (3), Cat (other) (3), Retriever - Golden (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Tiletamine Hcl & Zolazepam Hcl) are Circling - neurological disorder (see also 'Behavioural disorders') (2), Hernia NOS (2), Surgical site disorder (2), Fever (2). Of the 15 reports with a coded outcome, Recovered/Normal is the leading category at 40.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Tiletamine Hcl & Zolazepam Hcl).

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial